Five Prime Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Five Prime Therapeutics, Inc.
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.
Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Amgen, Inc.